drugset / Trial / NCT01790438
A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare LY2605541 and human insulin isophane suspension (NPH) using the following measures for participants treated for up to 26 weeks: * Change in participants' overall blood sugar control * The rate of night time low blood sugar episodes * The number of participants that reach blood sugar targets without low night time blood sugar episodes * The total number of low blood sugar episodes reported
Timeline
- Start
- 2013-03
- Primary completion
- 2014-05
- Completion
- 2014-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Human Insulin NPH | Protein / enzyme biologic | 10 iu | Subcutaneous |
| Subject | Insulin Peglispro | Protein / enzyme biologic | 10 iu | Subcutaneous |